Trial Profile
A phase I, single-center, open-label, randomized study to evaluate the pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide release in chinese male healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Pasireotide (Primary)
- Indications Acromegaly; Cushing syndrome; Neuroendocrine tumours
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 20 Nov 2015 New trial record